PharVision Advisers’s NiSource NI Stock Holding History

PharVision Advisers’s Portfolio NI Stock Details NI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,326	Closed	-$222K	–	461
2025 Q4	$222K	Buy	+5,326	New	+$228K	0.11%	472

Other funds holding NI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PharVision Advisers's NI Position: Q1 2026 in Review

PharVision Advisers sold out of NiSource (NI) in Q1 2026, closing a stake of 5,326 shares — an estimated $222K sold.

PharVision Advisers first reported a position in NI in Q4 2025 and held it in 1 quarter. The position peaked at $222K in Q4 2025. 877 funds tracked by Wall St. Rank hold NI as of Q1 2026.

PharVision Advisers reported no remaining NiSource position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 5,326 NiSource shares in Q1 2026, an estimated $222K.
PharVision Advisers first reported a position in NiSource in Q4 2025 and held it in 1 quarter.
PharVision Advisers's NiSource position peaked at $222K in Q4 2025.
877 funds tracked by Wall St. Rank held NiSource as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.